Download PDF
Semin Respir Crit Care Med 2007; 28(2): 243-252
DOI: 10.1055/s-2007-976495
Published by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Progress in Respiratory Virus Vaccine Development

Alexander C. Schmidt1
  • 1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Further Information

Publication History

Publication Date:
25 April 2007 (online)

    Permissions and Reprints

ABSTRACT

Viral respiratory infections continue to cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing acute respiratory disease, vaccine development has to focus on a limited number of pathogens (i.e., agents that commonly cause serious lower respiratory disease). Inactivated and, more recently, live attenuated influenza virus vaccines are the mainstay of interpandemic influenza prevention, but vaccines are not available yet for other important viruses such as respiratory syncytial virus, metapneumovirus, the parainfluenza viruses, and avian influenza viruses with pandemic potential. Reverse genetics systems that allow rational vaccine development are now widely used, and considerable progress has been made in preclinical and clinical development of novel respiratory virus vaccines.

KEYWORDS

Vaccine - influenza virus - parainfluenza virus - metapneumovirus - respiratory syncytial virus - clinical trial

REFERENCES

  • 1 The World Health Report: 2005: Make Every Mother and Child Count. Geneva: WHO; 2005
    Google Scholar
  • 2 Falsey A R, Hennessey P A, Formica M A, Cox C, Walsh E E. Respiratory syncytial virus infection in elderly and high-risk adults.  N Engl J Med. 2005;  352 1749-1759
    CrossrefPubMedGoogle Scholar
  • 3 Falsey A R, Formica M A, Hennessey P A, Criddle M M, Sullender W M, Walsh E E. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2006;  173 639-643
    PubMedGoogle Scholar
  • 4 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States.  JAMA. 2003;  289 179-186
    CrossrefPubMedGoogle Scholar
  • 5 Falsey A R, Walsh E E. Viral pneumonia in older adults.  Clin Infect Dis. 2006;  42 518-524
    CrossrefPubMedGoogle Scholar
  • 6 Subbarao K, Roberts A. Is there an ideal animal model for SARS?.  Trends Microbiol. 2006;  14 299-303
    CrossrefPubMedGoogle Scholar
  • 7 Stadler K, Rappuoli R. SARS: understanding the virus and development of rational therapy.  Curr Mol Med. 2005;  5 677-697
    CrossrefPubMedGoogle Scholar
  • 8 Gray G C, Goswami P R, Malasig M D et al.. Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics.  Clin Infect Dis. 2000;  31 663-670
    CrossrefPubMedGoogle Scholar
  • 9 Spier R E. On the need for, and the delivery of, cross-protective vaccines.  Vaccine. 2005;  23 2027-2029
    CrossrefPubMedGoogle Scholar
  • 10 Wilson J, Rowlands K, Rockett K et al.. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis.  J Infect Dis. 2005;  191 1705-1709
    CrossrefPubMedGoogle Scholar
  • 11 Crowe Jr J E, Williams J V. Immunology of viral respiratory tract infection in infancy.  Paediatr Respir Rev. 2003;  4 112-119
    CrossrefPubMedGoogle Scholar
  • 12 Guarner J, Paddock C D, Shieh W J et al.. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season.  Clin Infect Dis. 2006;  43 132-140
    CrossrefPubMedGoogle Scholar
  • 13 Zhang L, Peeples M E, Boucher R C, Collins P L, Pickles R J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.  J Virol. 2002;  76 5654-5666
    CrossrefPubMedGoogle Scholar
  • 14 Collins P L, Chanock R M, Murphy B R. Respiratory syncytial virus. In: Knipe DM, Howley PM, Griffin DE, et al Fields Virology. Vol 1. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2001: 1443-1486
    Google Scholar
  • 15 Collins P L, Murphy B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.  Proc Am Thorac Soc. 2005;  2 166-173
    CrossrefPubMedGoogle Scholar
  • 16 Lemanske R F. Viral infections and asthma inception.  J Allergy Clin Immunol. 2004;  114 1023-1026
    CrossrefPubMedGoogle Scholar
  • 17 Everard M L. The relationship between respiratory syncytial virus infections and the development of wheezing and asthma in children.  Curr Opin Allergy Clin Immunol. 2006;  6 56-61
    PubMedGoogle Scholar
  • 18 Psarras S, Papadopoulos N G, Johnston S L. Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing.  Paediatr Respir Rev. 2004;  5(Suppl A) S179-S184
    CrossrefPubMedGoogle Scholar
  • 19 Hacking D, Hull J. Respiratory syncytial virus-viral biology and the host response.  J Infect. 2002;  45 18-24
    CrossrefPubMedGoogle Scholar
  • 20 Puthothu B, Krueger M, Forster J, Heinzmann A. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes.  J Infect Dis. 2006;  193 438-441
    CrossrefPubMedGoogle Scholar
  • 21 Hoebee B, Bont L, Rietveld E et al.. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis.  J Infect Dis. 2004;  189 239-247
    CrossrefPubMedGoogle Scholar
  • 22 Mills J, Van Kirk J E, Wright P F, Chanock R M. Experimental respiratory syncytial virus infection of adults: possible mechanisms of resistance to infection and illness.  J Immunol. 1971;  107 123-130
    PubMedGoogle Scholar
  • 23 Watt P J, Robinson B S, Pringle C R, Tyrrell D A. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines.  Vaccine. 1990;  8 231-236
    CrossrefPubMedGoogle Scholar
  • 24 Kulkarni A B, Collins P L, Bacik I et al.. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.  J Virol. 1995;  69 1261-1264
    PubMedGoogle Scholar
  • 25 Plotnicky-Gilquin H, Robert A, Chevalet L et al.. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.  J Virol. 2000;  74 3455-3463
    CrossrefPubMedGoogle Scholar
  • 26 Plotnicky-Gilquin H, Cyblat-Chanal D, Aubry J P et al.. Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.  J Virol. 2002;  76 10203-10210
    CrossrefPubMedGoogle Scholar
  • 27 Group TI-RS . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.  Pediatrics. 1998;  102(3 Pt 1) 531-537
    CrossrefPubMedGoogle Scholar
  • 28 Crowe Jr J E. Influence of maternal antibodies on neonatal immunization against respiratory viruses.  Clin Infect Dis. 2001;  33 1720-1727
    CrossrefPubMedGoogle Scholar
  • 29 Crowe Jr J E, Firestone C Y, Murphy B R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.  J Immunol. 2001;  167 3910-3918
    PubMedGoogle Scholar
  • 30 Karron R A, Wright P F, Belshe R B et al.. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.  J Infect Dis. 2005;  191 1093-1104
    CrossrefPubMedGoogle Scholar
  • 31 Nolan S M, Surman S R, Amaro-Carambot E, Collins P L, Murphy B R, Skiadopoulos M H. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.  Vaccine. 2005;  23 4765-4774
    CrossrefPubMedGoogle Scholar
  • 32 McAuliffe J M, Surman S R, Newman J T et al.. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.  J Virol. 2004;  78 2029-2036
    CrossrefPubMedGoogle Scholar
  • 33 Bukreyev A, Belyakov I M, Berzofsky J A, Murphy B R, Collins P L. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.  J Virol. 2001;  75 12128-12140
    CrossrefPubMedGoogle Scholar
  • 34 Bukreyev A, Skiadopoulos M H, McAuliffe J, Murphy B R, Collins P L, Schmidt A C. More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?.  Proc Natl Acad Sci USA. 2002;  99 16987-16991
    CrossrefPubMedGoogle Scholar
  • 35 Schmidt A C, Wenzke D R, McAuliffe J M et al.. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.  J Virol. 2002;  76 1089-1099
    CrossrefPubMedGoogle Scholar
  • 36 Kim H W, Canchola J G, Brandt C D et al.. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.  Am J Epidemiol. 1969;  89 422-434
    PubMedGoogle Scholar
  • 37 Piedra P A. Clinical experience with respiratory syncytial virus vaccines.  Pediatr Infect Dis J. 2003;  22(Suppl 2) S94-S99
    CrossrefPubMedGoogle Scholar
  • 38 Kneyber M C, Kimpen J L. Advances in respiratory syncytial virus vaccine development.  Curr Opin Investig Drugs. 2004;  5 163-170
    PubMedGoogle Scholar
  • 39 Johnson T R, Graham B S. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.  Pediatr Infect Dis J. 2004;  23(Suppl 1) S46-S57
    PubMedGoogle Scholar
  • 40 Openshaw P J, Culley F J, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease.  Vaccine. 2001;  20(Suppl 1) S27-S31
    CrossrefPubMedGoogle Scholar
  • 41 Piedra P A, Cron S G, Jewell A et al.. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.  Vaccine. 2003;  21 2448-2460
    CrossrefPubMedGoogle Scholar
  • 42 Munoz F M, Piedra P A, Glezen W P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.  Vaccine. 2003;  21 3465-3467
    CrossrefPubMedGoogle Scholar
  • 43 Ison M G, Johnston S L, Openshaw P, Murphy B, Hayden F. Current research on respiratory viral infections: Fifth International Symposium.  Antiviral Res. 2004;  62 75-110
    CrossrefPubMedGoogle Scholar
  • 44 Wright P F, Karron R A, Madhi S A et al.. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.  J Infect Dis. 2006;  193 573-581
    CrossrefPubMedGoogle Scholar
  • 45 Wright P F, Karron R A, Belshe R B et al.. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.  J Infect Dis. 2000;  182 1331-1342
    CrossrefPubMedGoogle Scholar
  • 46 Biacchesi S, Skiadopoulos M H, Yang L et al.. Recombinant human metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.  J Virol. 2004;  78 12877-12887
    CrossrefPubMedGoogle Scholar
  • 47 Biacchesi S, Pham Q N, Skiadopoulos M H, Murphy B R, Collins P L, Buchholz U J. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates.  J Virol. 2005;  79 12608-12613
    CrossrefPubMedGoogle Scholar
  • 48 Buchholz U J, Biacchesi S, Pham Q N et al.. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity.  J Virol. 2005;  79 6588-6597
    CrossrefPubMedGoogle Scholar
  • 49 Pham Q N, Biacchesi S, Skiadopoulos M H, Murphy B R, Collins P L, Buchholz U J. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo.  J Virol. 2005;  79 15114-15122
    CrossrefPubMedGoogle Scholar
  • 50 Skiadopoulos M H, Surman S, Tatem J M et al.. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.  J Virol. 1999;  73 1374-1381
    PubMedGoogle Scholar
  • 51 Karron R A, Belshe R B, Wright P F et al.. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.  Pediatr Infect Dis J. 2003;  22 394-405
    CrossrefPubMedGoogle Scholar
  • 52 Belshe R B, Newman F K, Tsai T F et al.. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.  J Infect Dis. 2004;  189 462-470
    CrossrefPubMedGoogle Scholar
  • 53 Belshe R B, Newman F K, Anderson E L et al.. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.  J Infect Dis. 2004;  190 2096-2103
    CrossrefPubMedGoogle Scholar
  • 54 van Wyke Coelingh K L, Winter C C, Tierney E L, London W T, Murphy B R. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.  J Infect Dis. 1988;  157 655-662
    CrossrefPubMedGoogle Scholar
  • 55 Karron R A, Makhene M, Gay K, Wilson M H, Clements M L, Murphy B R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.  Pediatr Infect Dis J. 1996;  15 650-654
    CrossrefPubMedGoogle Scholar
  • 56 Greenberg D P, Walker R E, Lee M S et al.. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.  J Infect Dis. 2005;  191 1116-1122
    CrossrefPubMedGoogle Scholar
  • 57 Schmidt A C, McAuliffe J M, Huang A et al.. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.  J Virol. 2000;  74 8922-8929
    CrossrefPubMedGoogle Scholar
  • 58 Newman J T, Riggs J M, Surman S R et al.. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.  J Virol. 2004;  78 2017-2028
    CrossrefPubMedGoogle Scholar
  • 59 Bartlett E J, Amaro-Carambot E, Surman S R, Collins P L, Murphy B R, Skiadopoulos M H. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.  Vaccine. 2006;  24 2674-2684
    CrossrefPubMedGoogle Scholar
  • 60 Bartlett E J, Amaro-Carambot E, Surman S R et al.. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.  Vaccine. 2005;  23 4631-4646
    CrossrefPubMedGoogle Scholar
  • 61 Van Cleve W, Amaro-Carambot E, Surman S R et al.. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.  Virology. 2006;  352 61-73
    CrossrefPubMedGoogle Scholar
  • 62 Belshe R B, Gruber W C, Mendelman P M et al.. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.  J Pediatr. 2000;  136 168-175
    CrossrefPubMedGoogle Scholar
  • 63 Belshe R, Lee M S, Walker R E, Stoddard J, Mendelman P M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.  Expert Rev Vaccines. 2004;  3 643-654
    CrossrefPubMedGoogle Scholar
  • 64 Belshe R B, Mendelman P M, Treanor J et al.. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children.  N Engl J Med. 1998;  338 1405-1412
    CrossrefPubMedGoogle Scholar
  • 65 Stephenson I, Gust I, Pervikov Y, Kieny M P. Development of vaccines against influenza H5.  Lancet Infect Dis. 2006;  6 458-460
    PubMedGoogle Scholar
  • 66 Luke C J, Subbarao K. Vaccines for pandemic influenza.  Emerg Infect Dis. 2006;  12 66-72
    PubMedGoogle Scholar
  • 67 Stephenson I, Nicholson K G, Wood J M, Zambon M C, Katz J M. Confronting the avian influenza threat: vaccine development for a potential pandemic.  Lancet Infect Dis. 2004;  4 499-509
    PubMedGoogle Scholar
  • 68 Fauci A S. Pandemic influenza threat and preparedness.  Emerg Infect Dis. 2006;  12 73-77
    PubMedGoogle Scholar
  • 69 Palese P. Making better influenza virus vaccines?.  Emerg Infect Dis. 2006;  12 61-65
    PubMedGoogle Scholar
  • 70 Treanor J J, Campbell J D, Zangwill K M, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.  N Engl J Med. 2006;  354 1343-1351
    CrossrefPubMedGoogle Scholar
  • 71 Bresson J L, Perronne C, Launay O et al.. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.  Lancet. 2006;  367 1657-1664
    CrossrefPubMedGoogle Scholar
  • 72 Chen H, Matsuoka Y, Swayne D et al.. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.  Vaccine. 2003;  21 4430-4436
    CrossrefPubMedGoogle Scholar
  • 73 Karron R. Phase I Inpatient Evaluation of a Live Attenuated H9N2 ca Reassortant Vaccine in Healthy Adults Born after 1968. 2005 http://Accessed 09/20/2006: www.who.int/vaccine_research/diseases/influenza/mtg_021205/en/index3.html
    Google Scholar
  • 74 Suguitan A L, McAuliffe J, Mills K L et al.. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.  PLoS Med. 2006;  3 1541-1555
    PubMedGoogle Scholar

Alexander C SchmidtM.D. 

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health

50 South Dr., Rm. 6511, Bethesda, MD 20892-8007

Email: schmidta@niaid.nih.gov

      >